I agree except most shareholders are merely looking for significant progress. It’s not unfair to expect something substantial after all this time. If the call is merely about Cyrus’ return and “we’re still working on the FDA’s request,” a drop is inevitable.

But everyone here knows they’ll just buy more if that happens.

We are moving forward, towards greener pastures, it’s just a matter of how fast or slow.